CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare CollPlant Biotechnologies to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.
Risk and Volatility
CollPlant Biotechnologies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares CollPlant Biotechnologies and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $318,000.00 | -$11.49 million | -0.34 |
| CollPlant Biotechnologies Competitors | $715.43 million | $10.31 million | -18.30 |
CollPlant Biotechnologies’ rivals have higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares CollPlant Biotechnologies and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
| CollPlant Biotechnologies Competitors | -12,319.70% | -407.93% | -30.95% |
Insider and Institutional Ownership
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for CollPlant Biotechnologies and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| CollPlant Biotechnologies Competitors | 9932 | 15324 | 45736 | 1605 | 2.54 |
CollPlant Biotechnologies currently has a consensus price target of $120.00, indicating a potential upside of 2,486.21%. As a group, “Biotechnology” companies have a potential upside of 132.80%. Given CollPlant Biotechnologies’ higher probable upside, research analysts plainly believe CollPlant Biotechnologies is more favorable than its rivals.
Summary
CollPlant Biotechnologies rivals beat CollPlant Biotechnologies on 8 of the 13 factors compared.
About CollPlant Biotechnologies
CollPlant Biotechnologies is an Israel-based regenerative medicine company developing products and technologies based on recombinant human collagen (rhCollagen). Its proprietary production process uses genetically engineered plants to produce human collagen, offering an alternative to collagen sourced from animals or human tissue. The company’s rhCollagen platform is intended for applications including tissue repair, 3D bioprinting and medical aesthetics. Its development work includes bioinks and other collagen-based materials designed for use in regenerative medicine and tissue engineering.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
